ADNF Polypeptide Therapy for Neurodegenerative Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with visual evoked potential impairment and/or speech impairment, such as autism spectrum disorder, intellectual disability, and Alzheimer's disease, are inadequate in addressing the underlying neuroprotective needs.
Innovation Solution
Administration of a therapeutically effective amount of an ADNF polypeptide with neurotrophic/neuroprotective activity in an in vitro cortical neuron culture assay to treat diseases associated with visual evoked potential impairment and/or speech impairment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases associated with visual evoked potential impairment and speech impairment, then treatment coverage is maintained, but neuroprotective efficacy is insufficient
Solution Approach 1:
The patent applies universality by demonstrating that ADNF polypeptides can treat multiple neurodegenerative and developmental disorders (Alzheimer's disease, autism spectrum disorder, intellectual disability, tauopathies) through a single mechanism of action. The polypeptide serves multiple therapeutic functions across different disease indications, resolving the contradiction between maintaining broad treatment coverage and achieving sufficient neuroprotective efficacy.
2Productivity
If ADNF polypeptides are administered to treat neurodegenerative and developmental disorders, then cognitive function and functional activities of daily living are improved, but treatment complexity increases
Solution Approach 1:
The patent applies the extraction principle by isolating and administering the specific neuroprotective component (ADNF polypeptide) rather than using complex combination therapies. This extracts the essential therapeutic element needed to improve cognitive function and daily living activities, simplifying the treatment approach while maintaining efficacy.
3Reliability
If ADNF polypeptides are used to address underlying neuroprotective needs, then disease progression is slowed, but treatment cost increases
Solution Approach 1:
The patent applies parameter changes by modifying the biochemical parameters of the treatment through the use of recombinant ADNF polypeptide production methods. This allows for optimized dosing and administration parameters that control disease progression while managing treatment cost through efficient manufacturing processes.
Data Source
AI summary
Uses of ADNF polypeptides in therapy are provided. Accordingly, there is provided a method of treating a disease associated with visual evoked potential impairment and/or speech impairment that is not due to vocal disturbance and in which the subject suffers from the visual evoked potential impairment and/or speech impairment, the method comprising administering to the subject a therapeutically effective amount of an ADNF polypeptide, wherein said ADNF polypeptide has a neurotrophic/neuroprotective activity in an in vitro cortical neuron culture assay.